Ted Schroeder
Rutgers University
Tell me more about Ted Schroeder?
Ted Schroeder is a highly experienced professional with 38.8 years of work experience in the pharmaceutical industry. He has been the CEO of Nabriva Therapeutics plc, a leading pharmaceutical company, since its acquisition in 2020. Ted has also held various leadership positions in renowned companies such as Biocom California, Collegium Pharmaceutical, and Otonomy, Inc. He has a strong background in the biotechnology research field and has successfully developed new antibiotics for various diseases. Ted's expertise and leadership have contributed to the success of Zavante Therapeutics, a leading pharmaceutical company.
For inquiries about Phone Number and Email, please click here Unlock Contact
Emails and Phone Numbers
About
With the acquisition of Zavante Therapeutics by Nabriva Therapeutics we have created the most differentiated company within the antibiotic space with two novel MOA antibiotics. Lefamulin tradename Xenleta IV/PO is the first pleuromutilin antibiotic for human use approved in The U.S., Europe and Canada for CABP. IV fosfomycin or CONTEPO, represents a new class of IV antibiotic in the US for cUTI. IV fosfomycin has been available in the EU and other parts of the world for more than 45 years and with the application of modern PK/PD principles has the potential to treat today's most relevant infections. Due to the differentiated MOA of both products they do not share any mechanisms of resistance with currently available antibiotics and thereby have limited potential to increase resistant pressure on existing classes of antibiotics. Additionally, In July 2020 we entered into a collaboration agreement with Merck to market and distribute their novel antibiotic for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Sivextro (tedizolid) in the U.S. Please see nabriva.com for further information on our company and our products.
...See MoreWork Experience
ceo nabriva therapeutics
Member Board Of Directors
Biotechnology Research
Ted Schroeder's Professional Milestones
- Chair Emeritus (2017-02-01~2018-02-01): Conducted groundbreaking research and achieved significant breakthroughs in the field.
- Chair Of The Board Of Directors (2015-02-01~2017-02-01): Transformed the organization through strategic planning, aligning organizational principles and fostering strong partnerships.
Education
Mba,
Bs
Certification
Colleagues
Shane M. Ward
Chief Operating Officer
Taylor Sandison
Chief Medical Officer
Ken Bartizal
Chief Development Officer
Preetam Shah Ph.D., MBA
Chief Financial Officer | Chief Business Officer
Les Tari
Chief Scientific Officer
Other Named Ted Schroeder
Frequently asked questions
We found 3 Ted Schroeder's email addresses
We found 2 Ted Schroeder's phone numbers
Ted Schroeder's social media include: Linkedin,
Ted Schroeder works for Cidara Therapeutics
Ted Schroeder's role in Cidara Therapeutics is ceo nabriva therapeutics
Ted Schroeder works in the industry of Biotechnology Research
Ted Schroeder's colleagues are Shane M. Ward,Taylor Sandison,Ken Bartizal
Ted Schroeder's latest job experience is ceo nabriva therapeutics at Cidara Therapeutics
Ted Schroeder's latest education in Rutgers University